Bemarituzumab

Amgen announced positive first quarter 2025 financial results, citing strong global demand across its product portfolio and successful new product launches.

Orphan drug sales reached $168 billion globally in 2023, with growth expected to moderate to just under 10% annually through 2028, according to Evaluate's latest report.

DelveInsight's comprehensive analysis reveals over 200 companies actively developing 220+ pipeline therapies for gastric cancer treatment, indicating significant industry investment in addressing this disease.

The FDA has approved Lumakras (sotorasib) combined with Vectibix (panitumumab) for treating KRAS G12C-mutated metastatic colorectal cancer in adults after prior chemotherapy.

A groundbreaking study reveals that combining SHP2 inhibitor (SHP099) with FGFR2 inhibitor (AZD4547) demonstrates significant therapeutic potential in FGFR2-amplified gastric cancer. The combination therapy not only enhances anti-tumor effects but also overcomes resistance to FGFR2 inhibitors, while simultaneously boosting immune response through T-cell activation. This dual-action approach could provide new treatment options for patients with limited therapeutic alternatives.